Iteos Home

Analyst Coverage

Home / Investors / Analyst Coverage

Analyst Coverage

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

Analyst Coverage

H.C. Wainwright
Ramakanth Swayampakula
JP Morgan
Brian Cheng
Piper Sandler
Christopher Raymond
SVB Leerink
Daina Graybosch
Wedbush
David Nierengarten

iTeos Therapeutics is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding iTeos Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of iTeos Therapeutics or its management. iTeos Therapeutics does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Child kissing a woman

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.